These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Comparison of unrelated cord blood transplantation and HLA-mismatched unrelated bone marrow transplantation for adults with leukemia. Atsuta Y; Morishima Y; Suzuki R; Nagamura-Inoue T; Taniguchi S; Takahashi S; Kai S; Sakamaki H; Kouzai Y; Kobayashi N; Fukuda T; Azuma H; Takanashi M; Mori T; Tsuchida M; Kawase T; Kawa K; Kodera Y; Kato S; Biol Blood Marrow Transplant; 2012 May; 18(5):780-7. PubMed ID: 22008851 [TBL] [Abstract][Full Text] [Related]
8. [Donor lymphocyte infusion for treatment of relapse of leukemia after HLA-mismatched hematopoietic stem cell transplantation]. Liu DH; Liu KY; Xu LP; Han W; Chen H; Chen YH; Zhang XH; Huang XJ Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):78-82. PubMed ID: 18681305 [TBL] [Abstract][Full Text] [Related]
9. Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center. Huang X; Liu D Clin Transpl; 2011; ():237-45. PubMed ID: 22755417 [TBL] [Abstract][Full Text] [Related]
10. [Present status and future prospects in reduced intensity stem cell transplantation]. Takaue Y Nihon Naika Gakkai Zasshi; 2005 Jul; 94(7):1421-7. PubMed ID: 16097602 [No Abstract] [Full Text] [Related]
11. Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation. Or R; Hadar E; Bitan M; Resnick IB; Aker M; Ackerstein A; Samuel S; Tsirigotis P; Gesundheit B; Slavin S; Shapira MY Biol Blood Marrow Transplant; 2006 Dec; 12(12):1295-301. PubMed ID: 17162211 [TBL] [Abstract][Full Text] [Related]
12. Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings. Davies JK; Koh MB; Lowdell MW Biol Blood Marrow Transplant; 2004 Apr; 10(4):259-68. PubMed ID: 15077224 [TBL] [Abstract][Full Text] [Related]
13. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686 [TBL] [Abstract][Full Text] [Related]
14. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia. Stevanović S; Nijmeijer BA; van Schie ML; Salvatori DC; Maas S; Griffioen M; Falkenburg JH Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532 [TBL] [Abstract][Full Text] [Related]
15. Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison. Wang Y; Liu DH; Xu LP; Liu KY; Chen H; Chen YH; Han W; Shi HX; Huang XJ Biol Blood Marrow Transplant; 2011 Jun; 17(6):821-30. PubMed ID: 20831895 [TBL] [Abstract][Full Text] [Related]
16. Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation. Ciceri F; Bonini C; Gallo-Stampino C; Bordignon C Cytotherapy; 2005; 7(2):144-9. PubMed ID: 16040393 [TBL] [Abstract][Full Text] [Related]
17. Immunology. A perfect mismatch. Kärre K Science; 2002 Mar; 295(5562):2029-31. PubMed ID: 11896262 [No Abstract] [Full Text] [Related]
18. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency. Al-Mousa H; Al-Shammari Z; Al-Ghonaium A; Al-Dhekri H; Al-Muhsen S; Al-Saud B; Arnaout R; Al-Seraihy A; Al-Jefri A; Al-Ahmari A; Ayas M; El-Solh H Biol Blood Marrow Transplant; 2010 Jun; 16(6):818-23. PubMed ID: 20079864 [TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China. Liu QF; Xu XJ; Chen YK; Sun J; Zhang Y; Fan ZP; Xu D; Jiang QL; Wei YQ; Huang F; Feng R; Liu XL; Xu B; Meng FY Ann Hematol; 2011 Mar; 90(3):331-41. PubMed ID: 20872002 [TBL] [Abstract][Full Text] [Related]
20. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]